Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin (Regulatory Post Marketing Commitment Plan).
Phase of Trial: Phase IV
Latest Information Update: 13 Jul 2010
At a glance
- Drugs Exemestane (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 24 Jun 2010 Planned number of patients changed from 450 to 451 as reported by ClinicalTrials.gov.
- 14 Jul 2009 New trial record